FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094981780> ?p ?o ?g. }

• W2094981780 endingPage "1032" @default.
• W2094981780 startingPage "1026" @default.
• W2094981780 abstract "Clinical & Experimental AllergyVolume 33, Issue 8 p. 1026-1032 Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma K. A. O'Hara, K. A. O'Hara Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, Western Australian Institute for Medical Research and Centre for Medical Research, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorM.-A. Kedda, M.-A. Kedda Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, Western Australian Institute for Medical Research and Centre for Medical Research, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorP. J. Thompson, P. J. Thompson Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorD. A. Knight, D. A. Knight Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, andSearch for more papers by this author K. A. O'Hara, K. A. O'Hara Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, Western Australian Institute for Medical Research and Centre for Medical Research, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorM.-A. Kedda, M.-A. Kedda Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, Western Australian Institute for Medical Research and Centre for Medical Research, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorP. J. Thompson, P. J. Thompson Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, and The CRC for Asthma, Sydney, AustraliaSearch for more papers by this authorD. A. Knight, D. A. Knight Asthma and Allergy Research Institute Inc., QE II Medical Centre, Nedlands, Western Australia, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, Nedlands, Australia, andSearch for more papers by this author First published: 05 August 2003 https://doi.org/10.1046/j.1365-2222.2003.01714.xCitations: 33 Kirrily A. O'Hara, Asthma and Allergy Research Institute, Ground Floor, E Block, QE II Medical Centre, Hospital Avenue, Nedlands, Western Australia 6009, Australia. E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54: 577 – 89. 2 National Asthma Council Australia (10 December, 2002) Report on the cost of asthma in Australia, [online]. Available from: http://www.nationalasthma.org.au/publications/costs/apn.html, 15 December, 2002. 3 Busse WW, Lemanske RF Jr. Advances in immunology: asthma. N Engl J Med 2001; 344: 350 – 62. 4 Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in asthma. Curr Opin Pulmon Med 2000; 6: 15 – 20. 5 Laitinen LA, Laitinen A. Structural and cellular changes in asthma. Eur Respir Rev 1994; 4: 348 – 51. 6 Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001 – 6. 7 Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194 – 200. 8 Busse W, Elias J, Sheppard D, Banks-Schlegel S. Airway remodeling and repair. Am J Respir Crit Care Med 1999; 160: 1035 – 42. 9 Elson GC, Lelievre E, Guillet C et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci 2000; 3: 867 – 72. 10 Senaldi G, Varnum BC, Sarmiento U et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL- 6 family. Proc Natl Acad Sci 1999; 96: 11458 – 63. 11 Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297 – 314. 12 Morgan K, Marsters P, Morley S et al. Oncostatin M induced alpha1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3′ enhancer. Biochem J 2002; 365: 555 – 60. 13 Hermanns HM, Radtke S, Schaper F, Heinrich PC, Behrmann I. Non-redundant signal transduction of interleukin-6-type cytokines: the adapter protein Shc is specifically recruited to the oncostatin M receptor. J Biol Chem 2000; 275: 40742 – 8. 14 Auguste P, Guillet C, Fourcin M et al. Signaling of type II oncostatin M receptor. J Biol Chem 1997; 272: 15760 – 4. 15 Ernst M, Novak U, Nicholson SE, Layton JE, Dunn AR. The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3. J Biol Chem 1999; 274: 9729 – 37. 16 Ohtani T, Ishihara K, Atsumi T et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3-and SHP2-mediated signals in immune responses. Immunity 2000; 12: 95 – 105. 17 Rose TM, Bruce AG. Oncostatin M is a member of a cytokine family that includes leukemia- inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci 1991; 88: 8641 – 45. 18 Mosley B, De Imus C, Friend D et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271: 32635 – 43. 19 Scaffidi A, Mutsaers S, Moodley Y et al. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002; 136: 793 – 801. 20 Gosset P, Tsicopoulos A, Wallaert B et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 88: 561 – 71. 21 Einarsson O, Geba GP, Zhu Z, Landry M, Elias JA. Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. J Clin Invest 1996; 97: 915 – 24. 22 Gadient RA, Patterson PH. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999; 17: 127 – 37. 23 Benigni F, Villa P, Demitri MT et al. Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity. Mol Med 1995; 1: 568 – 75. 24 Shoyab M, Malik N, Wallace PM.(1998) Oncostatin M. New York: Academic Press Limited. 25 Horn D, Fitzpatrick WC, Gompper PT et al. Regulation of cell growth by recombinant oncostatin M. Growth Factors 1990; 2: 157 – 65. 26 Gomez-Lechon MJ. Oncostatin M: signal transduction and biological activity. Life Sci 1999; 65: 2019 – 30. 27 Loy JK, Davidson TJ, Berry KK, Macmaster JF, Danle B, Durham SK. Oncostatin M: development of a pleiotropic cytokine. Toxicol Pathol 1999; 27: 151 – 5. 28 Wallace PM, MacMaster JF, Rouleau KA et al. Regulation of inflammatory responses by oncostatin M. J Immunol 1999; 162: 5547 – 55. 29 Wallace PM, Brown TJ. Oncostatin M for treating inflammation. United States patent. United States. 1999. New York, NY: Bristol-Myers Squibb Company. 30 Grenier A, Dehoux M, Boutten A et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999; 93: 1413 – 21. 31 Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 1987; 139: 2977 – 83. 32 Suda T, Chida K, Todate A et al. Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine 2002; 17: 335 – 40. 33 Boutten A, Venembre P, Seta N et al. Oncostatin M is a potent stimulator of alpha1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. Am J Respir Cell Mol Biol 1998; 18: 511 – 20. 34 Cichy J, Rose-John S, Travis J. Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem J 1998; 329: 335 – 9. 35 Kerr C, Langdon C, Graham F, Gauldie J, Hara T, Richards CD. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression in vivo in mice. J Interferon Cytokine Res 1999; 19: 1195 – 205. 36 Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991; 147: 2175 – 80. 37 Lee YC, Lee HB, Rhee YK, Song CH. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001; 31: 1623 – 30. 38 Richards CD, Shoyab M, Brown TJ, Gauldie J. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 1993; 150: 5596 – 03. 39 Koshy PJ, Lundy CJ, Rowan AD et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002; 46: 961 – 7. 40 Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000; 157: 1187 – 96. 41 Ihn H, Tamaki K. Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 2000; 165: 2149 – 55. 42 Duncan MR, Hasan A, Berman B. Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts. J Invest Dermatol 1995; 104: 128 – 3. 43 Bamber B, Reife RA, Haugen HS, Clegg CH. Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease. J Mol Med 1998; 76: 61 – 69. 44 Cawston TE, Curry VA et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998; 41: 1760 – 71. 45 Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5 – 17. 46 Holgate ST. Epithelial damage and response. Clin Exp Allergy 2000; 30 (Suppl 1): 37 – 41. 47 Ihn H, LeRoy EC, Trojanowska M. Oncostatin M stimulates transcription of the human alpha2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 1997; 272: 24666 – 72. 48 Richards CD, Kerr C, Tong L, Langdon C. Modulation of extracellular matrix using adenovirus vectors. Biochem Soc Trans 2002; 30: 107 – 11. 49 Richards CD, Langdon C, Botelho F, Brown TJ, Agro A. Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte–macrophage colony-stimulating factor by synovial and lung fibroblasts. J Immunol 1996; 156: 343 – 9. 50 Lahiri T, Laporte JD, Moore PE, Panettieri RA Jr, Shore SA. Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells. Am J Physiol (Lung Cell Mol Physiol) 2001; 280: 1225 – 32. 51 Knight DA, Asokananthan N, Watkins DN, Misso NL, Thompson PJ, Stewart GA. Oncostatin M synergises with house dust mite proteases to induce the production of PGE(2) from cultured lung epithelial cells. Br J Pharmacol 2000; 131: 465 – 72. 52 Langdon C, Kerr C, Tong L, Richards CD. Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. J Immunol 2003; 170: 548 – 55. 53 Modur V, Feldhaus MJ, Weyrich AS et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997; 100: 158 – 68. 54 Yao L, Pan J, Setiadi H, Patel KD, McEver RP. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 1996; 184: 81 – 92. 55 Wahl AF, Wallace PM. Oncostatin M in the anti-inflammatory response. Ann Rheum Dis 2001; 60 (Suppl. 3): iii75 – 80. 56 Knight D, Carroll N, Lenzo J, McKay K, James A, Thompson P. Immunohistochemical localisation of oncostatin M receptors in human airways: altered pattern of expression in asthma. Eur Respir J 1999; 14: 528S. 57 Richards C, Shoyab M, Gauldie J, Brown TJ. Regulation of cellular invasiveness. United State's Patent. United States. 1998. New York, NY, Bristol Meyers Squibb Company; Hamilton, CA: McMaster University. 58 Ma Y, Streiff RJ, Liu J, Spence MJ, Vestal RE. Cloning and characterization of human oncostatin M promoter. Nucleic Acids Res 1999; 27: 4649 – 57. 59 Malik N, Kallestad JC, Gunderson NL et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989; 9: 2847 – 53. 60 Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149 – 57. 61 O'Brien CA, Manolagas SC. Isolation and characterization of the human gp130 promoter Regulation by STATS. J Biol Chem 1997; 272: 15003 – 10. Citing Literature Volume33, Issue8August 2003Pages 1026-1032 ReferencesRelatedInformation" @default.
• W2094981780 created "2016-06-24" @default.
• W2094981780 creator A5029966863 @default.
• W2094981780 creator A5030526109 @default.
• W2094981780 creator A5030528419 @default.
• W2094981780 creator A5052598796 @default.
• W2094981780 date "2003-08-01" @default.
• W2094981780 modified "2023-10-17" @default.
• W2094981780 title "Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma" @default.
• W2094981780 cites W1516383449 @default.
• W2094981780 cites W1530725542 @default.
• W2094981780 cites W1541529837 @default.
• W2094981780 cites W1586080609 @default.
• W2094981780 cites W1779691448 @default.
• W2094981780 cites W1806775765 @default.
• W2094981780 cites W1853965397 @default.
• W2094981780 cites W1894088506 @default.
• W2094981780 cites W1974992664 @default.
• W2094981780 cites W1975224746 @default.
• W2094981780 cites W1975809383 @default.
• W2094981780 cites W1986142113 @default.
• W2094981780 cites W1988193415 @default.
• W2094981780 cites W1989046970 @default.
• W2094981780 cites W2017013436 @default.
• W2094981780 cites W2017223857 @default.
• W2094981780 cites W2031491552 @default.
• W2094981780 cites W2036614649 @default.
• W2094981780 cites W2041566569 @default.
• W2094981780 cites W2044798615 @default.
• W2094981780 cites W2046661997 @default.
• W2094981780 cites W2058332480 @default.
• W2094981780 cites W2073516670 @default.
• W2094981780 cites W2078556117 @default.
• W2094981780 cites W2079666008 @default.
• W2094981780 cites W2082427057 @default.
• W2094981780 cites W2089783160 @default.
• W2094981780 cites W2096748441 @default.
• W2094981780 cites W2103691455 @default.
• W2094981780 cites W2132842779 @default.
• W2094981780 cites W2140531258 @default.
• W2094981780 cites W2144223627 @default.
• W2094981780 cites W2152295044 @default.
• W2094981780 cites W2158356076 @default.
• W2094981780 cites W2162214575 @default.
• W2094981780 cites W2166867978 @default.
• W2094981780 cites W2217861510 @default.
• W2094981780 cites W2279720479 @default.
• W2094981780 cites W3023821264 @default.
• W2094981780 cites W4248469839 @default.
• W2094981780 cites W4313333818 @default.
• W2094981780 cites W88943984 @default.
• W2094981780 doi "https://doi.org/10.1046/j.1365-2222.2003.01714.x" @default.
• W2094981780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12911774" @default.
• W2094981780 hasPublicationYear "2003" @default.
• W2094981780 type Work @default.
• W2094981780 sameAs 2094981780 @default.
• W2094981780 citedByCount "37" @default.
• W2094981780 countsByYear W20949817802012 @default.
• W2094981780 countsByYear W20949817802013 @default.
• W2094981780 countsByYear W20949817802014 @default.
• W2094981780 countsByYear W20949817802015 @default.
• W2094981780 countsByYear W20949817802018 @default.
• W2094981780 countsByYear W20949817802019 @default.
• W2094981780 countsByYear W20949817802020 @default.
• W2094981780 countsByYear W20949817802021 @default.
• W2094981780 countsByYear W20949817802022 @default.
• W2094981780 crossrefType "journal-article" @default.
• W2094981780 hasAuthorship W2094981780A5029966863 @default.
• W2094981780 hasAuthorship W2094981780A5030526109 @default.
• W2094981780 hasAuthorship W2094981780A5030528419 @default.
• W2094981780 hasAuthorship W2094981780A5052598796 @default.
• W2094981780 hasConcept C105922876 @default.
• W2094981780 hasConcept C11988809 @default.
• W2094981780 hasConcept C141071460 @default.
• W2094981780 hasConcept C203014093 @default.
• W2094981780 hasConcept C2776042228 @default.
• W2094981780 hasConcept C2777667943 @default.
• W2094981780 hasConcept C2778690821 @default.
• W2094981780 hasConcept C2780942790 @default.
• W2094981780 hasConcept C71924100 @default.
• W2094981780 hasConceptScore W2094981780C105922876 @default.
• W2094981780 hasConceptScore W2094981780C11988809 @default.
• W2094981780 hasConceptScore W2094981780C141071460 @default.
• W2094981780 hasConceptScore W2094981780C203014093 @default.
• W2094981780 hasConceptScore W2094981780C2776042228 @default.
• W2094981780 hasConceptScore W2094981780C2777667943 @default.
• W2094981780 hasConceptScore W2094981780C2778690821 @default.
• W2094981780 hasConceptScore W2094981780C2780942790 @default.
• W2094981780 hasConceptScore W2094981780C71924100 @default.
• W2094981780 hasIssue "8" @default.
• W2094981780 hasLocation W20949817801 @default.
• W2094981780 hasLocation W20949817802 @default.
• W2094981780 hasOpenAccess W2094981780 @default.
• W2094981780 hasPrimaryLocation W20949817801 @default.
• W2094981780 hasRelatedWork W1881051652 @default.
• W2094981780 hasRelatedWork W1987192197 @default.
• W2094981780 hasRelatedWork W2021510332 @default.
• W2094981780 hasRelatedWork W2033263543 @default.

• next